SLC5A2 and type 2 diabetes mellitus: Apart from the recognized renal protective mechanism of inhibiting oxidative stress, inflammation and fibrosis, reducing blood glucose and blood pressure (Kashihara et al., 2020; Wang J. et al., 2021), SGLT-2 inhibitors were also reported to alter the intestinal microbiota in type 2 diabetic rats and patients (Deng L. et al., 2022; Deng X. et al., 2022; Lee et al., 2018; Wang X. et al., 2022; Yang M. et al., 2020).